Alaunos Therapeutics financials
$0.8875−7.60%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $5.0K | $10.0K | $5.0K | $2.9M |
| Gross profit | $5.0K | $10.0K | $5.0K | $2.9M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$4.2M | -$4.8M | -$34.3M | -$35.1M |
| Net income | -$4.3M | -$4.7M | -$35.1M | -$37.7M |
| Net margin | −85640.0% | −46790.0% | −702800.0% | −1291.2% |
| Diluted EPS | $-2.20 | $-2.92 | $-21.97 | $-26.10 |
| EBITDA | -$4.2M | -$4.8M | -$26.2M | -$32.5M |
| Operating cash flow | -$2.9M | -$5.0M | -$30.1M | -$29.2M |
| Free cash flow | -$3.0M | -$5.0M | -$30.3M | -$29.4M |
| Diluted shares | 1.9M | 1.6M | 1.6M | 1.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $1.4M | $1.1M | $6.1M | $39.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $19.5M |
| Total assets | $3.0M | $2.8M | $8.3M | $64.9M |
| Total liabilities | $813.0K | $692.0K | $2.0M | $26.4M |
| Shareholders' equity | $2.2M | $2.1M | $6.3M | $38.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology